Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1

Area of Science:

• Cancer biology
• Genomics
• Drug discovery

Background:

• ATRX (alpha-thalassemia/mental retardation syndrome X-linked) is a chromatin remodeler frequently mutated in various cancers.
• Loss of ATRX function can lead to genomic instability and altered cellular vulnerabilities.
• Targeting specific molecular weaknesses in cancer cells is crucial for developing effective precision therapies.

Purpose of the Study:

• To identify novel therapeutic vulnerabilities in cancer cells with ATRX loss.
• To evaluate WEE1 kinase as a potential target in ATRX-deficient malignancies.
• To provide a preclinical rationale for WEE1 inhibitor-based cancer treatment.

Main Methods:

• Genome-wide CRISPR-Cas9 negative loss-of-function screening was employed.
• Cellular models with depleted ATRX expression were utilized.
• The study identified WEE1 kinase as a key vulnerability.

Main Results:

• WEE1 kinase was identified as a synthetic lethal target in cells lacking ATRX.
• This suggests that inhibiting WEE1 kinase could be particularly effective in ATRX-mutated cancers.
• The findings highlight a specific therapeutic window for WEE1 inhibition.

Conclusions:

• WEE1 kinase represents a promising therapeutic vulnerability in ATRX-deficient cancers.
• The WEE1 inhibitor AZD1775 (adavosertib) may be a viable option for precision medicine trials in these patients.
• This research contributes to the development of targeted therapies for a range of pediatric and adult malignancies with ATRX loss.